Recently, <i>nab</i>-sirolimus, an albumin-bound mTOR inhibitor, was approved by the Food and Drug Administration (FDA) for PEComas, which harbor a TSC mutation, and this drug remains the only FDA-approved systemic treatment for these tumors. This evidence concerns the gene MTOR and neoplasm with perivascular epithelioid cell differentiation.